Local drug delivery - The early Berlin experience: Single drug administration versus sustained release

EuroIntervention

Volumn 7, Issue SUPPL. K, 2011, Pages

  Speck, Ulrich ^a   Scheller, Bruno ^b   Rutsch, Wolfgang ^a   Laule, Michael ^a   Stangl, Verena ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Local drug delivery; Paclitaxel; Paclitaxel coated balloon catheter; Restenosis

Indexed keywords

EPOTHILONE DERIVATIVE; FLAVONOID; IODIXANOL; IOPROMIDE; IOSIMENOL; MEGLUMINE IOXAGLATE PLUS SODIUM IOXAGLATE; NONIONIC CONTRAST MEDIUM; PACLITAXEL; PACLITAXEL CERIBATE; PROTEASOME INHIBITOR; RAPAMYCIN; ZOTAROLIMUS;

ACUTE HEART INFARCTION; ARTERY INTIMA PROLIFERATION; BALLOON CATHETER; CELL PROLIFERATION; CONCENTRATION RESPONSE; CORONARY ARTERY BYPASS GRAFT; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG EXPOSURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; HUMAN; IN-STENT RESTENOSIS; NONHUMAN; REVIEW; SUSTAINED RELEASE FORMULATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; BERLIN; CARDIOVASCULAR AGENTS; CATHETERS; CELL PROLIFERATION; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY VESSELS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; HUMANS; MODELS, ANIMAL; PACLITAXEL; SIROLIMUS; SWINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 80355128284     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV7SKA4     Document Type: Review

References (29)

1. Rodriguez AE. Emerging drugs for coronary restenosis: the role of systemic oral agents in the stent era. Expert Opin Emerging Drugs 2009;14:561-576.
2. Waksman R, Pakala R. Drug-eluting balloon. The comeback kid? Circ Cardiovasc Intervent 2009;2:352-358.
3. Iofina E, Langenberg R, Blindt R, Kühl H, Kelm M, Hoffmann R. Polymer-based paclitaxel-eluting stents are superior to nonpolymer- based paclitaxel-eluting stents in the treatment of de novo coronary lesions. Am J Cardiol 2006;98:1022-1027. (Pubitemid 44486136)
4. Serruys PW, Sianos G, Abizaid A, Aoki J, den Heijer P, Bonnier H, Smits P, McClean D, Verheye S, Belardi J, Condado J, Pieper M, Gambone L, Bressers M, Symons J, Sousa E, Litvack F. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform. The paclitaxel instent controlled elution study (PISCES). J Am Coll Cardiol 2005;46:253-260. (Pubitemid 40966852)
5. Herdeg C, Goehring-Frischholz K, Zuern C, Geisler T, Hartmann U, Hoevelborn T, Haase KK, Gawaz M. Local catheterbased delivery of antithrombotic or antiproliferative drugs: a new concept for prevention of restenosis. Thromb Res 2008;123:236-243.
6. Batchelor WB, Granger CB, Kleiman NS, Phillips HR, Ellis SG, Betriu A, Criger DA, Stebbins AL, Topol EJ, Califf RM. A comparison of ionic versus nonionic contrast medium during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (GUSTO IIb). Am J Cardiol 2000;85:692-697. (Pubitemid 30133387)
7. Scheller B, Hennen B, Pohl A, Schieffer H, Markwirth T. Acute and subacute stent occlusion. Risk-reduction by ionic contrast media. Eur Heart J 2001;22:385-391. (Pubitemid 32622443)
8. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-1014.
9. Seligson AL, Terry RC, Bressi JC, Douglass JG. Sovak M. A new prodrug of paclitaxel: synthesis of protaxel. Anticancer Drugs 2001;12:305-313. (Pubitemid 32453435)
10. Sovak M, Terry R, Abramjuk C, Faberová V, Fiserova M, Laznicek M, Leuschner J, Malinak J, Zahradnik P, Masner O, Seligson A. Iosimenol, a low-viscosity nonionic dimer: preclinical physicochemistry, pharmacology, and pharmacokinetics. Invest Radiol 2004;39:171-181. (Pubitemid 38263923)
11. Clauß W, Scheller B, Schmitt A, Sovak M, Speck U. No difference among modern contrast media's effect on neointimal proliferation and restenosis following coronary stenting in pigs. Invest Radiol 2003;38:743-749. (Pubitemid 37444946)
12. Scheller B, Speck U, Romeike B, Schmitt A, Sovak M, Böhm M, Stoll HP: Contrast Media as a Carrier for Local Drug Delivery: Successful Inhibition of Neointimal Proliferation in the Porcine Coronary Stent Model. Eur Heart J 2003;24:1462-1467. (Pubitemid 36961837)
13. Scheller B, Speck U, Schmitt A, Böhm M, Nickenig G. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol 2003;42:1415-1420. (Pubitemid 37267283)
14. Rutsch W, Scheller B, Borges AC, Braeutigam M, Clever Y, Cremers B, Dietz U, Richter C and Speck U. Intracoronary local paclitaxel delivery by X-ray contrast media for in-stent restenosis: a clinical pilot study to assess safety and tolerability. Manuscript submitted.
15. Scheller B, Speck U, Böhm M. Prevention of restenosis - is angioplasty the answer? Heart 2007;93:539-541.
16. Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G: Paclitaxel balloon coating - a novel method for prevention and therapy of restenosis. Circulation 2004;110:810-814. (Pubitemid 39096008)
17. Perkins LEL. Preclinical models of restenosis and their application in the evaluation of drug-eluting stent systems. Veterinary Pathology 2010;47:58-76.
18. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006;255:2113-2124. (Pubitemid 44749319)
19. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 2008;97:773-781.
20. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi J-P, Claussen CD, Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. New Engl J Med 2008;358:689-699. (Pubitemid 351240748)
21. Werk M, Langner S MD; Reinkensmeier B, BoettcherH-F, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J. Inhibition of restenosis in femoropopliteal arteries. Paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358-1365.
22. Axel DI, Kunert W, Göggelmann C, Oberhoff M, Herdeg C, Küttner A, Wild DH, Brehm BR, Riessen R, Köveker G, Karsch KR. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-645. (Pubitemid 27329445)
23. Clever YP, Cremers B, Krauß B, Böhm M, Speck U, Laufs U, Scheller B. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells. EuroIntervention 2011;7:118-128.
24. Scheller B. The Invatec Program: Product Features and Clinical Trials. CRT 2011, Washington DC, USA, 28.02.2011.
25. Mori T, Kinoshita Y, Watanabe A, Yamaguchi T, Hosokawa K, Honjo H, Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro. Cancer Chemother Pharmacol 2006;58:665-672. (Pubitemid 44167392)
26. Cremers B, Toner JL, Schwartz LB, von Oepen R, Speck U, Kaufels N, Clever YP, Mahnkopf M, Böhm M, Scheller. Inhibition of coronary neointimal hyperplasia in swine using a novel zotarolimus- eluting balloon catheter. Am J Cardiol 2009;104(6) (Supplement): TCT-444.
27. Stangl V, Laule M. Personal communication.
28. Sheiban I, Anselmino M, Moretti C, Biondi-Zoccai G, Galloni M, Vignolini C, Mattoni M, Sciuto F, Omede P, Trevi GP. Effect of a novel drug-eluted balloon coated with Genistein before stent implantation in porcine coronary arteries. Clin Res Cardiol 2008;97:891-898.
29. Scheller B, Speck U, et al., 2009; (patent application) published by Dadino RC, Zjao JZ. US 2010/0331816.